Literature DB >> 35834169

National survey on the secondary preventive measures for coronary artery disease among interventional cardiologists: a report from the Japanese Association of Cardiovascular Intervention and Therapeutics.

Sumio Yamada1, Takuji Adachi2, Hironobu Ashikawa3, Kuya Funaki3, Shun Kohsaka4, Yuji Ikari5, Tetsuya Amano6.   

Abstract

Insights from recent clinical trial testing revascularization strategies have interested interventional cardiologists in optimal medical therapy and secondary prevention modalities. As no large-scale survey has been recently conducted, this report presents the results of a nationwide survey on interventionists' concerns regarding secondary prevention after percutaneous coronary intervention (PCI) and discusses medical support system needs in Japan. A questionnaire to assess the status and challenges of secondary prevention interventions by interventional cardiologists during outpatient visits was supplied to Cardiovascular Interventional Technology (CVIT)-certificated hospitals. This was answered by representative cardiologists of each hospital and comprised three queries: (1) the necessity of outpatient cardiac rehabilitation to promote post-PCI lifestyle guidance; (2) the feasibility of providing lifestyle guidance; and (3) the barriers to lifestyle guidance, during outpatient visits. Questions 1 and 2 were answered using a 5-point Likert scale. Survey responses were received from 391 hospitals (54.9% of 712 CVIT-certificated facilities). For Question 1, 327 hospitals (84.1%) answered "agree", and 386 hospitals (98.7%) answered "agree" or "somewhat agree". For Question 2, 10% of hospitals answered "agree", and "agree" and "somewhat agree" amounted to less than 50%. For Question 3, 83.5% of the facilities answered lack of time as the major reason). The next reasons included an early reverse referral to family doctors after PCI, and a lack of managerial advantage (60% and 40% of the hospitals, respectively). In conclusion, interventionists are concerned about secondary prevention for their patients. The issues clarified in the survey will be important for developing next-generation secondary prevention systems.
© 2022. The Author(s) under exclusive licence to Japanese Association of Cardiovascular Intervention and Therapeutics.

Entities:  

Keywords:  Cardiac rehabilitation; Coronary artery disease; Interventionist; Secondary prevention

Year:  2022        PMID: 35834169     DOI: 10.1007/s12928-022-00874-y

Source DB:  PubMed          Journal:  Cardiovasc Interv Ther        ISSN: 1868-4297


  5 in total

1.  Cardiac rehabilitation in the digital era.

Authors:  Amitabh C Pandey; Jessica R Golbus; Eric J Topol
Journal:  Lancet       Date:  2021-07-03       Impact factor: 79.321

2.  Feasibility of home-based cardiac rehabilitation using an integrated telerehabilitation platform in elderly patients with heart failure: A pilot study.

Authors:  Atsushi Kikuchi; Tatsunori Taniguchi; Kei Nakamoto; Fusako Sera; Tomohito Ohtani; Takahisa Yamada; Yasushi Sakata
Journal:  J Cardiol       Date:  2021-02-10       Impact factor: 3.159

3.  Optimal medical therapy with or without PCI for stable coronary disease.

Authors:  William E Boden; Robert A O'Rourke; Koon K Teo; Pamela M Hartigan; David J Maron; William J Kostuk; Merril Knudtson; Marcin Dada; Paul Casperson; Crystal L Harris; Bernard R Chaitman; Leslee Shaw; Gilbert Gosselin; Shah Nawaz; Lawrence M Title; Gerald Gau; Alvin S Blaustein; David C Booth; Eric R Bates; John A Spertus; Daniel S Berman; G B John Mancini; William S Weintraub
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

4.  Long-term prognosis of patients with acute myocardial infarction in the era of acute revascularization (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] registry).

Authors:  Narumi Okura; Hiroshi Ogawa; Johji Katoh; Takao Yamauchi; Nobuhisa Hagiwara
Journal:  Int J Cardiol       Date:  2011-03-12       Impact factor: 4.164

Review 5.  Optimal Medical Therapy as First-Line Therapy for Chronic Coronary Syndromes: Lessons from COURAGE, BARI 2D, FAME 2, and ISCHEMIA.

Authors:  David L Brown
Journal:  Cardiovasc Drugs Ther       Date:  2021-11-12       Impact factor: 3.947

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.